Abstract
The treatment of metastatic colorectal cancer has evolved over the last two decades with the FDA approval of several cytotoxic, biological, and targeted agents. In this paper, we review the impact of sidedness, RAS, BRAF, HER-2, and other immune biomarkers on metastatic colorectal cancer treatment selection and sequencing in both the palliative and curative intent settings.
Keywords:
biomarkers; chemotherapy; colorectal cancer; immunotherapy; targeted therapy.
© 2019 Wiley Periodicals, Inc.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / genetics
-
Colorectal Neoplasms / pathology*
-
ErbB Receptors / antagonists & inhibitors
-
Humans
-
Molecular Targeted Therapy
-
Mutation
-
Neoadjuvant Therapy
-
Precision Medicine*
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Receptor, ErbB-2 / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
ERBB2 protein, human
-
ErbB Receptors
-
Receptor, ErbB-2
-
Proto-Oncogene Proteins B-raf